Rest of World — Total revenues
Gilead Sciences Rest of World — Total revenues increased by 9.3% to $889.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.8%, from $915.00M to $889.00M. Over 3 years (FY 2022 to FY 2025), Rest of World — Total revenues shows a downward trend with a -3.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market expansion or higher demand for therapies in international territories, while a decrease may signal competitive pressure, regulatory hurdles, or pricing challenges in those regions.
Detailed definition
This metric represents the total gross revenue generated from pharmaceutical product sales and related services within g...
Peer comparison
Peers typically report this as 'International Revenue' or 'Rest of World' segment revenue, often excluding major markets like the U.S., Europe, or Japan depending on the company's specific reporting structure.
gild_segment_rest_of_world_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $982.00M | $982.00M | $982.00M | $982.00M | $842.00M | $842.00M | $842.00M | $842.00M | $894.00M | $879.00M | $929.00M | $827.00M | $915.00M | $842.00M | $933.00M | $813.00M | $889.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -14.3% | +0.0% | +0.0% | +0.0% | +6.2% | -1.7% | +5.7% | -11.0% | +10.6% | -8.0% | +10.8% | -12.9% | +9.3% |
| YoY Change | — | — | — | — | -14.3% | -14.3% | -14.3% | -14.3% | +6.2% | +4.4% | +10.3% | -1.8% | +2.3% | -4.2% | +0.4% | -1.7% | -2.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's rest of world — total revenues?
- Gilead Sciences (GILD) reported rest of world — total revenues of $889.00M in Q1 2026.
- How has Gilead Sciences's rest of world — total revenues changed year-over-year?
- Gilead Sciences's rest of world — total revenues decreased by 2.8% year-over-year, from $915.00M to $889.00M.
- What is the long-term trend for Gilead Sciences's rest of world — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's rest of world — total revenues has grown at a -3.7% compound annual growth rate (CAGR), from $3.93B to $3.50B.
- What does rest of world — total revenues mean?
- Total revenue generated from sales in geographic regions outside of the company's primary markets.